A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)
for Renal Cell Carcinoma, Clear Cell
Drug: Ipilimumab
6 locations incl. Boston
Sponsor: M.D. Anderson Cancer Center
Sex: All·Age: 18+
Code: NCT06708949·Phase 2·Recruiting